Skip to main content

Post-IPO Equity Therapeutics Companies

Explore 204 therapeutics startups that raised post-ipo equity funding. Access verified founder contact information and fundraising data.

Total Companies
204
Total Funding
$547.0M
Avg Funding
$136.8M
Cities
4

Export 204 Post-IPO Equity Therapeutics Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Lausanne, Switzerland
$60.0M
raised

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Oct 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$34.2M
raised

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

Oct 2022
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Carmel, United States
$2.8M
raised

NeurAxis develops neuromodulation therapies to address chronic and debilitating conditions in children.

Oct 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Boston, United States
$450.0M
raised

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Oct 2023
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Showing 201 to 204 of 204 companies

Ready to Connect with Post-IPO Equity Therapeutics Startups?

Get verified founder emails, funding details, and company data for 204 post-ipo equity therapeutics companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked